Centurylink Investment Management Company Decreased By $1.60 Million Its Apple (AAPL) Holding; 9 Analysts Are Bullish Sorrento Therapeutics, Inc. (SRNE) Last Week

Apple Inc. (NASDAQ:AAPL) Logo

Among 9 analysts covering Sorrento Therapeutics (NASDAQ:SRNE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sorrento Therapeutics had 27 analyst reports since July 29, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 24 report. Roth Capital initiated the stock with “Buy” rating in Thursday, August 3 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, December 7. The stock of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) earned “Buy” rating by FBR Capital on Thursday, June 15. The company was maintained on Thursday, August 10 by Oppenheimer. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 30. H.C. Wainwright maintained it with “Buy” rating and $35.0 target in Tuesday, February 20 report. H.C. Wainwright maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) on Tuesday, June 27 with “Buy” rating. H.C. Wainwright maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating on Monday, September 18. H.C. Wainwright has “Buy” rating and $20.0 target. The rating was maintained by Rodman & Renshaw on Tuesday, April 5 with “Buy”. See Sorrento Therapeutics, Inc. (NASDAQ:SRNE) latest ratings:

06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Maintain
01/03/2018 Broker: Oppenheimer Rating: Buy New Target: $11.0 Maintain
20/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $35.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
23/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
19/01/2018 Broker: Oppenheimer Rating: Buy New Target: $9.0 Maintain
15/11/2017 Broker: Oppenheimer Rating: Buy New Target: $6.0 Maintain

Centurylink Investment Management Company decreased Apple Inc (AAPL) stake by 14.97% reported in 2017Q4 SEC filing. Centurylink Investment Management Company sold 9,497 shares as Apple Inc (AAPL)’s stock declined 3.81%. The Centurylink Investment Management Company holds 53,962 shares with $9.13M value, down from 63,459 last quarter. Apple Inc now has $870.60 billion valuation. The stock increased 1.89% or $3.19 during the last trading session, reaching $171.58. About 34.61M shares traded. Apple Inc. (NASDAQ:AAPL) has risen 19.49% since April 5, 2017 and is uptrending. It has outperformed by 7.94% the S&P500.

Investors sentiment increased to 0.73 in Q4 2017. Its up 0.03, from 0.7 in 2017Q3. It increased, as 50 investors sold AAPL shares while 1023 reduced holdings. 151 funds opened positions while 637 raised stakes. 2.98 billion shares or 0.18% more from 2.97 billion shares in 2017Q3 were reported. Johnson Inv Counsel Incorporated has 789,825 shares for 3.34% of their portfolio. New York-based Cibc Ww Mkts has invested 2.62% in Apple Inc. (NASDAQ:AAPL). Eastern State Bank holds 2.55% of its portfolio in Apple Inc. (NASDAQ:AAPL) for 225,112 shares. Oakwood Cap Limited Com Ca invested in 59,162 shares or 2.22% of the stock. Magnetar Financial Ltd Company, a Illinois-based fund reported 7,975 shares. Moreover, Wellington Grp Ltd Liability Partnership has 1.14% invested in Apple Inc. (NASDAQ:AAPL). Berkshire Asset Ltd Limited Liability Company Pa reported 25,060 shares. Impax Asset Management Ltd Llc stated it has 244,875 shares. Lbmc Investment Advsrs Ltd Liability accumulated 5,977 shares. Drw Ltd Co holds 1.28% or 71,976 shares. Tower Cap Ltd Co (Trc) invested 1.73% of its portfolio in Apple Inc. (NASDAQ:AAPL). Profit Investment Management Ltd holds 14,212 shares or 1.84% of its portfolio. Df Dent &, Maryland-based fund reported 14,336 shares. First City Capital Management Incorporated invested 1.02% in Apple Inc. (NASDAQ:AAPL). Aqr Cap Management Limited reported 1.36% stake.

Since October 3, 2017, it had 0 insider buys, and 2 insider sales for $5.39 million activity. Riccio Daniel J. also sold $2.73M worth of Apple Inc. (NASDAQ:AAPL) shares. Another trade for 56,808 shares valued at $8.79 million was sold by SCHILLER PHILIP W. 63,388 shares valued at $9.78 million were sold by AHRENDTS ANGELA J on Tuesday, October 3.

Analysts await Apple Inc. (NASDAQ:AAPL) to report earnings on May, 1. They expect $2.71 EPS, up 29.05% or $0.61 from last year’s $2.1 per share. AAPL’s profit will be $13.75B for 15.83 P/E if the $2.71 EPS becomes a reality. After $3.89 actual EPS reported by Apple Inc. for the previous quarter, Wall Street now forecasts -30.33% negative EPS growth.

Among 53 analysts covering Apple Inc. (NASDAQ:AAPL), 34 have Buy rating, 1 Sell and 18 Hold. Therefore 64% are positive. Apple Inc. has $220.0 highest and $11 lowest target. $172.60’s average target is 0.59% above currents $171.58 stock price. Apple Inc. had 388 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Friday, November 3 by Morgan Stanley. Cowen & Co maintained Apple Inc. (NASDAQ:AAPL) on Friday, October 21 with “Outperform” rating. The rating was maintained by Canaccord Genuity on Friday, January 8 with “Buy”. Needham maintained Apple Inc. (NASDAQ:AAPL) rating on Friday, February 2. Needham has “Buy” rating and $210.0 target. The stock of Apple Inc. (NASDAQ:AAPL) has “Equal-Weight” rating given on Friday, October 13 by Barclays Capital. The company was maintained on Wednesday, June 28 by KeyBanc Capital Markets. The stock of Apple Inc. (NASDAQ:AAPL) earned “Outperform” rating by FBR Capital on Friday, February 12. Deutsche Bank maintained Apple Inc. (NASDAQ:AAPL) on Monday, July 17 with “Hold” rating. On Tuesday, August 2 the stock rating was downgraded by Daiwa Securities to “Outperform”. The rating was maintained by Cowen & Co on Tuesday, August 25 with “Market Perform”.

Since January 23, 2018, it had 2 insider buys, and 4 sales for $11.11 million activity. $566,037 worth of stock was sold by ABG Management Ltd on Monday, February 5. Asia Pacific MedTech (BVI) Ltd sold $5.18 million worth of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) on Tuesday, January 23. 90,000 shares were bought by Ng George K, worth $895,500. Ji Henry also bought $642,770 worth of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) shares.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $500.66 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It has a 42.31 P/E ratio. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.

Investors sentiment increased to 1.53 in Q4 2017. Its up 0.86, from 0.67 in 2017Q3. It increased, as 7 investors sold Sorrento Therapeutics, Inc. shares while 8 reduced holdings. 11 funds opened positions while 12 raised stakes. 8.46 million shares or 1.81% more from 8.31 million shares in 2017Q3 were reported. 29,568 were accumulated by Gagnon Secs Lc. Wells Fargo & Co Mn holds 0% or 2,500 shares in its portfolio. 100,621 were accumulated by Deutsche Fincl Bank Ag. Citadel Advsr Limited Liability reported 12,586 shares stake. Geode Capital Management Llc reported 460,620 shares. Vanguard Group Inc owns 2.41 million shares or 0% of their US portfolio. Blackrock holds 968,284 shares. Royal National Bank Of Canada holds 0% or 147 shares in its portfolio. Goldman Sachs Group reported 32,703 shares or 0% of all its holdings. Prelude Cap Ltd Llc accumulated 9,695 shares. California Pub Employees Retirement holds 36,800 shares or 0% of its portfolio. Bancshares Of Mellon has 0% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Alpine Global Lc holds 0.03% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 37,882 shares. Barclays Public Ltd Company invested 0% of its portfolio in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Price T Rowe Associate Incorporated Md, a Maryland-based fund reported 77,300 shares.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Institutional Positions Chart